AstraZeneca Q4 net loss at Rs 33 cr on voluntary recall; production halt
Columnist Sanjeev Bhasin takes a look at the factors that influenced market movement in the week gone by, and what one should expect in the coming week.
AstraZeneca Pharma India today reported a net loss of Rs 33 crore for the quarter ended March 31, 2012, due to a voluntary recall of sterile products and temporary halt of production at its Bangalore facility.
The company had posted a net profit of Rs 8.35 crore for the quarter ended March 31,2011 AstraZeneca said in a filing to BSE.
Total income of the company stood at Rs 91.78 crore for the quarter ended March 31, 2012. It was Rs 126.73 crore for the corresponding period previous fiscal.
The company said its board of directors has recommended a dividend of Rs 3.50 per equity share of face value of Rs 2 each for the financial year ended March 31, 2012.
AstraZeneca operates through two entities, AstraZeneca Pharma India Ltd and AstraZeneca India Pvt Ltd in the country.